Invitation to presentation of the Q4 Interim Report, on January 27 at 2 pm CET
Uppsala, Sweden – January 20, 2022 – As previously communicated Orexo will announce the Q4 Interim Report, which also includes the 2021 Full Year Report, on January 27 at 8 am CET. The same day at 2 pm CET analysts, investors and media are invited to attend a presentation where Nikolaj Sørensen, CEO, Joseph DeFeo, CFO and Robert Rönn, SVP & Head of R&D will present the latest development. After the presentation a Q&A will be held. Questions can also be sent in advance to email@example.com, not later than 11 am CET.
Please view the instructions below on how to participate.
Telephone no.: SE: +46 850 558 374, UK: +44 333 300 9263, US: +1 646 722 4902
Prior to the event the presentation material will be available on the website under Investors/Reports, presentations
For further information, please contact:
Orexo AB (publ.)
Lena Wange, IR & Communications Director
Tel: +46 (0)18 780 88 00
Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental illness. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the US market for buprenorphine/naloxone products, where Orexo commercializes its lead product, ZUBSOLV®, for treatment of opioid use disorder. Total net sales for Orexo in 2020 amounted to SEK 664 million and the number of employees was 138. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.
For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.